Form 4: Applied Therapeutics COO Receives 350,000 Restricted Stock Units

Constantine Chinoporos, COO of Applied Therapeutics, was granted 350,000 Restricted Stock Units (RSUs) on March 24, 2025, under the company's 2019 Equity Incentive Plan.

Summary

• Constantine Chinoporos, the Chief Operating Officer and Chief Business Officer of Applied Therapeutics, Inc., received 350,000 Restricted Stock Units (RSUs) on March 24, 2025.
• These RSUs were granted under the company's 2019 Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of Applied Therapeutics' common stock.
• The RSUs vest over time, with one-fourth vesting on March 24, 2026, and the remaining shares vesting monthly thereafter, contingent upon continued service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of RSUs aligns the COO's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.

Risks

• The value of the RSUs is dependent on the future performance of Applied Therapeutics' stock, which is subject to market risks and company-specific factors.

Future Outlook

The vesting schedule of the RSUs suggests a commitment from the COO to remain with the company for at least the vesting period.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Granting RSUs to key executives is a standard practice in the pharmaceutical and biotech industries.
• Companies like Amgen, Gilead Sciences, and Biogen often use similar equity-based compensation plans to incentivize their leadership teams.
• The specific amount and vesting schedule can vary based on the executive's role, company performance, and industry benchmarks.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it incentivizes the COO to contribute to the company's long-term success.
• Employees may see it as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Applied Therapeutics, Constantine Chinoporos, Restricted Stock Units, RSUs, Equity Incentive Plan, Form 4, Beneficial Ownership, Officer Compensation